Abstract
Recently, the field of oncology has witnessed the introduction of several effective chemotherapeutic agents. Still, not all cancers respond to the use of conventional chemotherapy and thus combination therapy is an emerging weapon in the battle against cancer. There is emerging evidence in support of the use of Monoclonal antibodies (MoAbs) in cancer therapy. The mechanisms behind their efficacy are multi-faceted; they can kill tumor cells through antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis as well as target ligands or growth factor receptors favoring tumor growth. The interaction of the Fc domains of antibodies with the Fcγ (gamma) receptors is an essential checkpoint in ADCC. This interaction is strongly regulated and is largely dependent upon receptor conformation and number. It is accepted that germ-line single nucleotide polymorphisms (SNPs) and copy number variations (CNVs) have the potential to predict the outcome of therapy. The possibility of predicting patients response to monoclonal antibody therapy is of particular importance, as response rates are moderate, with the risk of serious side effects all at a high financial cost. This patent review provides an insight into the role of Fcγ receptors (FcγRs) genetic variation in Monoclonal Antibody-based anti-cancer therapy.
Keywords: Monoclonal antibody-based therapy, genetic polymorphism, copy number variations, single nucleotide polymorphism, pharmacogenomics, Alemtuzumab, Bevacizumab, Cetuximab, Ofatumumab, Rituximab, Trastuzumab
Recent Patents on Anti-Cancer Drug Discovery
Title: Insights into the Role of Fc Gamma Receptors (FcγRs) Genetic Variations in Monoclonal Antibody-Based Anti-Cancer Therapy
Volume: 5 Issue: 3
Author(s): Fabio Concetti and Valerio Napolioni
Affiliation:
Keywords: Monoclonal antibody-based therapy, genetic polymorphism, copy number variations, single nucleotide polymorphism, pharmacogenomics, Alemtuzumab, Bevacizumab, Cetuximab, Ofatumumab, Rituximab, Trastuzumab
Abstract: Recently, the field of oncology has witnessed the introduction of several effective chemotherapeutic agents. Still, not all cancers respond to the use of conventional chemotherapy and thus combination therapy is an emerging weapon in the battle against cancer. There is emerging evidence in support of the use of Monoclonal antibodies (MoAbs) in cancer therapy. The mechanisms behind their efficacy are multi-faceted; they can kill tumor cells through antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis as well as target ligands or growth factor receptors favoring tumor growth. The interaction of the Fc domains of antibodies with the Fcγ (gamma) receptors is an essential checkpoint in ADCC. This interaction is strongly regulated and is largely dependent upon receptor conformation and number. It is accepted that germ-line single nucleotide polymorphisms (SNPs) and copy number variations (CNVs) have the potential to predict the outcome of therapy. The possibility of predicting patients response to monoclonal antibody therapy is of particular importance, as response rates are moderate, with the risk of serious side effects all at a high financial cost. This patent review provides an insight into the role of Fcγ receptors (FcγRs) genetic variation in Monoclonal Antibody-based anti-cancer therapy.
Export Options
About this article
Cite this article as:
Concetti Fabio and Napolioni Valerio, Insights into the Role of Fc Gamma Receptors (FcγRs) Genetic Variations in Monoclonal Antibody-Based Anti-Cancer Therapy, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (3) . https://dx.doi.org/10.2174/157489210791760490
DOI https://dx.doi.org/10.2174/157489210791760490 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-inflammatory, Antioxidant, Lung and Liver Protective Activity of
<i>Galaxaura oblongata</i> as Antagonistic Efficacy against LPS using Hematological
Parameters and Immunohistochemistry as Biomarkers
Cardiovascular & Hematological Agents in Medicinal Chemistry Exploiting Protein Phosphatase Inhibitors Based on Cantharidin Analogues for Cancer Drug Discovery
Mini-Reviews in Medicinal Chemistry The Pathogenic Subpopulation of Th17 Cells in Obesity
Current Pharmaceutical Design Benzimidazole Heterocycle as a Privileged Scaffold in Antiviral Agents
Mini-Reviews in Organic Chemistry Is There a Clinical Future for Spermatogonial Stem Cells?
Current Stem Cell Research & Therapy A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity
Current Drug Targets The Need for Calcium Channels in Cell Proliferation
Recent Patents on Anti-Cancer Drug Discovery The Contractile Properties of Airway Smooth Muscle: How their Defects can be Linked to Asthmatic Airway Hyperresponsiveness?
Current Respiratory Medicine Reviews Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Extracellular Production of the Oncolytic Enzyme, L-Asparaginase, by Newly Isolated Streptomyces sp. Strain NEAE-95 as Potential Microbial Cell Factories: Optimization of Culture Conditions Using Response Surface Methodology
Current Pharmaceutical Biotechnology Protein-Protein Interaction Inhibitors: Small Molecules from Screening Techniques
Current Topics in Medicinal Chemistry In Utero Gene Therapy: Prospect and Future
Current Pharmaceutical Design Posttranslational Regulation of O6-Methylguanine-DNA Methyltransferase (MGMT) and New Opportunities for Treatment of Brain Cancers
Mini-Reviews in Medicinal Chemistry Histone Deacetylase Inhibitors in Psoriasis Therapy
Current Drug Targets - Inflammation & Allergy Overview of Brain Tumor Stem Cells – Implications for Treatment
Current Signal Transduction Therapy Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?
Current Cancer Drug Targets Potential Health Benefits of Berries
Current Nutrition & Food Science Repositioning of DHFR Inhibitors
Current Topics in Medicinal Chemistry Transplacental Transfer of Immunosuppressants and Biologics Used for the Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Biotechnology Targeting Kinase-activating Genetic Lesions to Improve Therapy of Pediatric Acute Lymphoblastic Leukemia
Current Medicinal Chemistry